Document is current
Any future updates will be listed below
-
Authors
Buse, John B https://orcid.org/0000-0002-9723-3876
Nordahl Christensen, Helene
Harty, Brian J
Cziraky, Mark J
Willey, Vincent J
Skibsted, Simon
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03596450 at ClinicalTrials.govnct03596450 at ClinicalTrials.govDocuments that mention this clinical trial
Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
https://doi.org/10.1136/bmjdrc-2022-003206
Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care
https://doi.org/10.1136/bmjdrc-2025-005180
Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial
https://doi.org/10.1136/bmjdrc-2025-005161
nct03596450 at ClinicalTrials.govDocuments that mention this clinical trial
Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
https://doi.org/10.1136/bmjdrc-2022-003206
Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care
https://doi.org/10.1136/bmjdrc-2025-005180
Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial
https://doi.org/10.1136/bmjdrc-2025-005161
Documents that mention this clinical trial
Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial
https://doi.org/10.1136/bmjdrc-2022-003206
Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care
https://doi.org/10.1136/bmjdrc-2025-005180
Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes: a randomized pragmatic clinical trial
https://doi.org/10.1136/bmjdrc-2025-005161
-
Funding
Funding for this research was provided by:
Novo Nordisk A/S (N/A)
- License Information
